Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
AUPH Stock | USD 8.98 0.03 0.34% |
Under 59% of all Aurinia Pharmaceuticals' traders are looking to take a long position. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that some traders are interested. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
Aurinia |
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS in Treating Lupus Nephritis at ASN Kidney Week 2024
Read at businesswire.com
Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Aurinia Pharmaceuticals Fundamental Analysis
We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Aurinia Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Aurinia Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Aurinia Pharmaceuticals Related Equities
BTAI | BioXcel Therapeutics | 5.71 | ||||
HEPA | Hepion Pharmaceuticals | 2.04 | ||||
TERN | Terns Pharmaceuticals | 1.38 | ||||
SRPT | Sarepta Therapeutics | 1.21 | ||||
AKRO | Akero Therapeutics | 1.16 | ||||
AXSM | Axsome Therapeutics | 1.10 | ||||
PTCT | PTC Therapeutics | 1.08 | ||||
MDGL | Madrigal Pharmaceuticals | 0.65 | ||||
EXEL | Exelixis | 0.62 | ||||
VKTX | Viking Therapeutics | 0.07 | ||||
TGTX | TG Therapeutics | 0.31 | ||||
MCRB | Seres Therapeutics | 4.17 |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |